A client with a peripheral doxorubicin extravasation received immediate infusion interruption, aspiration without flushing, intermittent cooling, elevation, and prescribed dexrazoxane. Creatinine clearance is 32 mL/min, so the antidote dose was reduced by 50%. Review the 3-day local, neurovascular, renal, and treatment trend. Select the best interpretation and ongoing plan.
Trend
Choose your responses, then check the answer.
Explanation
The smaller erythema, lower pain, minimal swelling, intact distal neurovascular findings, and absence of blistering, ulceration, or necrosis show improvement. Complete the renal-adjusted 3-day dexrazoxane course and continue local, blood-count, and renal monitoring. Symptom improvement is not a reason to stop the antidote early; the affected extremity should not be reused for doxorubicin access, and massage may spread residual vesicant and worsen tissue injury.
Quick answer The local trend is improving, and the client needs completion of the renal-adjusted 3-day dexrazoxane course with continued surveillance.
Why this is correct The Totect label uses 3 consecutive treatment days, begins within 6 hours, and requires a 50 percent dose reduction when creatinine clearance is below 40 mL/min. Decreasing pain and swelling without blistering support improvement but do not end follow-up.
Easy analogy or mental picture A shrinking spill mark is progress, not permission to stop the cleanup early.
Memory hook Better site plus complete antidote course plus continued monitoring.
NCLEX decision rule Evaluate both the tissue response and whether time-sensitive therapy, renal adjustment, and follow-up remain correct.
Why the other choices are wrong Stopping the antidote course early abandons the labeled regimen. Rechallenging the affected vein or assuming blood return proves recovery recreates risk.
References
1DailyMed: Doxorubicin Hydrochloride InjectionExtravasation recognition and immediate discontinuation
2FDA: Totect Prescribing InformationAnthracycline extravasation treatment within 6 hours and renal dose modification
3ONS/ASCO Antineoplastic Extravasation GuidelineEvidence-based antidote, thermal care, and escalation framework
Post-extravasation treatment trendImproving pain and swelling do not replace completion of the renal-adjusted antidote course and continued tissue, blood-count, and kidney monitoring.